

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

Applicant(s): Jeff A. ZABLOCKI et al.  
Title: N-PYRAZOLE A2A ADENOSINE RECEPTOR  
AGONISTS  
Filing Date: 06-22-1999  
Appl. No.: 09/338,185  
Issue Date: 06-11-2002  
Patent No.: 6,403,567  
Examiner: CRANE, Lawrence E.  
Group Art Unit: 1623  
Confirmation No.: 1072

**PETITION FOR CORRECTION OF INVENTORSHIP OF PATENT**  
**UNDER 37 C.F.R. §1.324**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Commissioner:

This is a petition for correction of error of inventors in the above issued patent. The petition is being filed pursuant to 37 C.F.R. § 1.324. It is respectfully requested that the Office issue a certificate correcting the error. As a courtesy, a Certificate of Correction indicating all of the inventors is included.

The above-listed patent currently lists Jeff A. ZABLOCKI, Elfatih O. ELZEIN, and Venkata P. PALLE as the inventors. Patentee submits that Luiz BELARDINELLI should also be named, in addition to Jeff A. ZABLOCKI, Elfatih O. ELZEIN, and Venkata P. PALLE, as the inventor of the above-listed patent. This petition requests that the Office correct the inventorship of the patent.

Pursuant to 37 C.F.R. § 1.324(b), enclosed herewith are the following documents:

1. Statement from the person being added as an inventor (Luiz BELARDINELLI).
2. Statement from the currently named inventors (Jeff A. ZABLOCKI, Elfatih O. ELZEIN, and Venkata P. PALLE).
3. Statement from Assignee (Gilead Sciences, Inc.) agreeing to the change of inventorship in the patent.
4. Statement under 37 C.F.R. § 3.73(c), establishing right of assignee to take action.
5. The fee required under 37 C.F.R. § 1.20(b), which is being paid via EFS-Web.

Also included is:

6. A Certificate of Correction requesting the addition of Luiz BELARDINELLI as an inventor of the above-listed patent.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date NOV. 4, 2012

By 

FOLEY & LARDNER LLP  
Customer Number: 103644  
Telephone: (650) 251-1104  
Facsimile: (650) 856-3710

Lorna L. Tanner  
Attorney for Applicants  
Registration No. 50,782

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Jeff A. ZABLOCKI et al.  
Title: N-PYRAZOLE A2A ADENOSINE  
RECEPTOR AGONISTS  
Filing Date: 06-22-1999  
Appl. No.: 09/338,185  
Issue Date: 06-11-2002  
Patent No.: 6,403,567  
Examiner: CRANE, Lawrence E.  
Group Art Unit: 1623  
Confirmation No.: 1072

**STATEMENT FROM THE PERSON BEING ADDED AS AN INVENTOR PURSUANT  
TO 37 C.F.R. § 1.324(b)(1)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Commissioner:

I, Luiz BELARDINELLI, the person signed below and who is being added as an inventor in the above-identified patent, have no disagreement in regard to the requested change of inventorship of this patent.

Respectfully submitted,

Date 10-26-2012

By   
Luiz BELARDINELLI

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Jeff A. ZABLOCKI et al.  
Title: N-PYRAZOLE A2A ADENOSINE  
RECEPTOR AGONISTS  
Filing Date: 06-22-1999  
Appl. No.: 09/338,185  
Issue Date: 06-11-2002  
Patent No.: 6,403,567  
Examiner: CRANE, Lawrence E.  
Group Art Unit: 1623  
Confirmation No.: 1072

**STATEMENT FROM CURRENTLY NAMED INVENTOR PURSUANT TO 37 C.F.R. §  
1.324(b)(1)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Commissioner:

I, Jeff A. ZABLOCKI, an inventor signed below and who is being retained as an inventor in the above-identified patent, make the following statement in support of the petition to correct the inventorship to name Luiz BELARDINELLI as an inventor of this patent. I have no disagreement with the requested change of inventorship of this patent.

Respectfully submitted,

Date Oct. 19, 2012

By Jeff A. Zablocki  
Jeff A. ZABLOCKI

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Jeff A. ZABLOCKI et al.  
Title: N-PYRAZOLE A2A ADENOSINE  
RECEPTOR AGONISTS  
Filing Date: 06-22-1999  
Appl. No.: 09/338,185  
Issue Date: 06-11-2002  
Patent No.: 6,403,567  
Examiner: CRANE, Lawrence E.  
Group Art Unit: 1623  
Confirmation No.: 1072

**STATEMENT FROM CURRENTLY NAMED INVENTOR PURSUANT TO 37 C.F.R. §  
1.324(b)(1)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Commissioner:

I, Elfatih O. ELZEIN, an inventor signed below and who is being retained as an inventor in the above-identified patent, make the following statement in support of the petition to correct the inventorship to name Luiz BELARDINELLI as an inventor of this patent. I have no disagreement with the requested change of inventorship of this patent.

Respectfully submitted,

Date 10-18-12

By Elfatih O. ELZEIN  
Elfatih O. ELZEIN

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Jeff A. ZABLOCKI et al.  
Title: N-PYRAZOLE A2A ADENOSINE  
RECEPTOR AGONISTS  
Filing Date: 06-22-1999  
Appl. No.: 09/338,185  
Issue Date: 06-11-2002  
Patent No.: 6,403,567  
Examiner: CRANE, Lawrence E.  
Group Art Unit: 1623  
Confirmation No.: 1072

**STATEMENT FROM CURRENTLY NAMED INVENTOR PURSUANT TO 37 C.F.R. §  
1.324(b)(1)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Commissioner:

I, Venkata P. PALLE, an inventor signed below and who is being retained as an inventor in the above-identified patent, make the following statement in support of the petition to correct the inventorship to name Luiz BELARDINELLI as an inventor of this patent. I have no disagreement with the requested change of inventorship of this patent.

Respectfully submitted,

Date October 26, 2012

By P.V.P.P. Alchamur  
Venkata P. PALLE

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***


Applicant(s): Jeff A. ZABLOCKI et al.  
Title: N-PYRAZOLE A2A  
ADENOSINE RECEPTOR  
AGONISTS  
Filing Date: 06-22-1999  
Appl. No.: 09/338,185  
Issue Date: 06-11-2002  
Patent No.: 6,403,567  
Examiner: CRANE, Lawrence E.  
Group Art Unit: 1623  
Confirmation No.: 1072

**STATEMENT FROM ASSIGNEE AGREEING TO CHANGE OF INVENTORSHIP IN  
PATENT PURSUANT TO 37 C.F.R. § 1.324(b)(2)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Commissioner:

Gilead Sciences, Inc., owner by assignment of the above-identified patent, said assignment being recorded on June 10, 2011 at Reel/Frame 026424/0925, and complying with the requirements of 37 C.F.R. § 3.73(c), hereby agrees to the change of inventorship of this patent as requested in the accompanying papers. Attached herewith is a "Statement under 37 C.F.R. § 3.73(c)," establishing the right of the assignee to take action in this case.

  
\_\_\_\_\_  
Signature

Eric Voelk, Director, Intellectual Property  
Name

10/31/12  
Date

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.  
(Also Form PTO-1050)

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

PATENT NO. : 6,403,567  
APPLICATION NO. : 09/338,185  
DATED : 06/11/2002  
INVENTOR(S) : Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle, Luiz Belardinelli

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title Page

Item [75] Inventors, add "**Luiz Belardinelli**, Palo Alto, all of CA (US)."

MAILING ADDRESS OF SENDER (Please do not use customer number below):

975 Page Mill Road  
Palo Alto, California 94304-1013

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer,

U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*



**STATEMENT UNDER 37 CFR 3.73(c)**

Applicant/Patent Owner: ZABLOCKI, et al.  
Application No./Patent No.: 6,403,567 Filed/Issue Date: 6/11/2002  
Titled: N-PYRAZOLE A2A ADENOSINE RECEPTOR AGONISTS  
Gilead Sciences, Inc., a Corporation  
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that, for the patent application/patent identified above, it is (choose **one** of options 1, 2, 3 or 4 below):

1. ☒ The assignee of the entire right, title, and interest.
2. ☐ An assignee of less than the entire right, title, and interest (check applicable box):
- ☐ The extent (by percentage) of its ownership interest is \_\_\_\_\_%. Additional Statement(s) by the owners holding the balance of the interest must be submitted to account for 100% of the ownership interest.
- ☐ There are unspecified percentages of ownership. The other parties, including inventors, who together own the entire right, title and interest are:

Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the entire right, title, and interest.

3. ☐ The assignee of an undivided interest in the entirety (a complete assignment from one of the joint inventors was made). The other parties, including inventors, who together own the entire right, title, and interest are:

Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the entire right, title, and interest.

4. ☐ The recipient, via a court proceeding or the like (e.g., bankruptcy, probate), of an undivided interest in the entirety (a complete transfer of ownership interest was made). The certified document(s) showing the transfer is attached.

The interest identified in option 1, 2 or 3 above (not option 4) is evidenced by either (choose **one** of options A or B below):

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Zablocki, Jeff A., Elzein, Elfatih O. and Palle, Venkata P. To: CV Therapeutics, Inc.

The document was recorded in the United States Patent and Trademark Office at  
Reel 010187, Frame 0341, or for which a copy thereof is attached.

2. From: Apex Merger Sub, Inc. and CV Therapeutics, Inc. To: Gilead Palo Alto, Inc.

The document was recorded in the United States Patent and Trademark Office at  
Reel 026627, Frame 0135, or for which a copy thereof is attached.

[Page 1 of 2]

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

**STATEMENT UNDER 37 CFR 3.73(c)**

3. From: Gilead Palo Alto, Inc. To: Gilead Sciences, Inc.

The document was recorded in the United States Patent and Trademark Office at  
Reel 026424, Frame 0925, or for which a copy thereof is attached.

4. From: Luiz Belardinelli To: Gilead Sciences, Inc.

The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

5. From: \_\_\_\_\_ To: \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

6. From: \_\_\_\_\_ To: \_\_\_\_\_


The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet(s).

☒ As required by 37 CFR 3.73(c)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature 

**Eric Voelk**

Printed or Typed Name

Date 10/31/12

Director, Intellectual Property

Title or Registration Number

**ASSIGNMENT - WORLDWIDE**

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor (hereinafter referred to singly and collectively as "ASSIGNOR") has sold, assigned, and transferred, and by these presents hereby sells, assigns, and transfers, unto

Gilead Sciences, Inc.  
333 Lakeside Drive  
Foster City, CA 94404

(hereinafter referred to as "ASSIGNEE") its successors and assigns, the full and exclusive right, title and interest for the United States, its territories and possessions, and all foreign countries in and to this invention relating to

**N-PYRAZOLE A2A ADENOSINE RECEPTOR AGONISTS**

as set forth in this United States Patent Application

*check one*      ☐ executed concurrently herewith,  
                  ☐ executed on \_\_\_\_\_,  
                  ☒ Serial No. 09/338,185    Filed 6/22/1999

as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified application and all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions and all improvements and modifications thereof, (c) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (e) the right to claim for any of said applications the full benefits and priority rights under the Patent Cooperation Treaty, the Paris Convention and any other international agreement; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, improvements, and modifications including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE, its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions, improvements, and modifications under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **Foley & Lardner LLP** the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of **Foley & Lardner LLP** do not personally represent ASSIGNOR OR ASSIGNOR's legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.

Executed this 26 day of October, 2012.

  
LUIZ BELARDINELLI

# CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

CIVIL CODE § 1189

State of California

County of San Mateo

On October 26, 2012 before me, Donna J. Macedo Notary Public

personally appeared Luiz Belardinelli


Here Insert Name and Title of the Officer

Name(s) of Signer(s)

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.



Place Notary Seal Above

Signature: Donna J. Macedo

Signature of Notary Public

## OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

### Description of Attached Document

Title or Type of Document: Assignment - worldwide

Document Date: October 26, 2012 Number of Pages: 3

Signer(s) Other Than Named Above: \_\_\_\_\_

### Capacity(ies) Claimed by Signer(s)

Signer's Name: \_\_\_\_\_

☐ Corporate Officer — Title(s): \_\_\_\_\_

☐ Individual

☐ Partner — ☐ Limited ☐ General

☐ Attorney in Fact

☐ Trustee

☐ Guardian or Conservator

☐ Other: \_\_\_\_\_

Signer Is Representing: \_\_\_\_\_

RIGHT THUMBPRINT  
OF SIGNER

Top of thumb here

Signer's Name: \_\_\_\_\_

☐ Corporate Officer — Title(s): \_\_\_\_\_

☐ Individual

☐ Partner — ☐ Limited ☐ General

☐ Attorney in Fact

☐ Trustee

☐ Guardian or Conservator

☐ Other: \_\_\_\_\_

Signer Is Representing: \_\_\_\_\_

RIGHT THUMBPRINT  
OF SIGNER

Top of thumb here